Parikh Nehal S, Howard Scott C, Chantada Guillermo, Israels Trijn, Khattab Mohammed, Alcasabas Patricia, Lam Catherine G, Faulkner Lawrence, Park Julie R, London Wendy B, Matthay Katherine K
Department of Pediatrics, Division of Hematology-Oncology, Connecticut Children's Medical Center, Hartford, Connecticut.
University of Memphis, Memphis, Tennessee.
Pediatr Blood Cancer. 2015 Aug;62(8):1305-16. doi: 10.1002/pbc.25501. Epub 2015 Mar 21.
Neuroblastoma is the most common extracranial solid tumor in childhood in high-income countries (HIC), where consistent treatment approaches based on clinical and tumor biological risk stratification have steadily improved outcomes. However, in low- and middle- income countries (LMIC), suboptimal diagnosis, risk stratification, and treatment may occur due to limited resources and unavailable infrastructure. The clinical practice guidelines outlined in this manuscript are based on current published evidence and expert opinions. Standard risk stratification and treatment explicitly adapted to graduated resource settings can improve outcomes for children with neuroblastoma by reducing preventable toxic death and relapse.
神经母细胞瘤是高收入国家（HIC）儿童期最常见的颅外实体瘤，在这些国家，基于临床和肿瘤生物学风险分层的一致治疗方法稳步改善了治疗效果。然而，在低收入和中等收入国家（LMIC），由于资源有限和基础设施不足，可能会出现诊断、风险分层和治疗欠佳的情况。本手稿中概述的临床实践指南基于当前已发表的证据和专家意见。明确适用于不同资源水平的标准风险分层和治疗方法，可通过减少可预防的毒性死亡和复发，改善神经母细胞瘤患儿的治疗效果。
